FDA 483 - Genzyme Corporation - March 18, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Genzyme Corporation in Ridgefield, NJ, a drug manufacturer, identified a significant issue regarding procedures to prevent microbiological contamination of sterile drug products. Specifically, the firm's smoke studies for the aseptic filling of Lovenox syringes were found to be inadequate, failing to demonstrate unidirectional airflow during critical interventions and assess observed air currents. This raises concerns about the sterility assurance of their products.
ID · b8d19728-3c57-41fd-af77-18918dce4914